Outcomes in Patients with Cancer-Associated Venous Thromboembolism Receiving Immune Checkpoint Inhibitors: A Matched Cohort Study

被引：0
|
作者：
Danielian, Pedro Luiz Lage Bodour [1 ]
Dave, Heloni M. [2 ]
Wei, Wei [3 ]
Patel, Mehrie H. [1 ]
Angelini, Dana Elizabeth [1 ]
Khorana, Alok A. [1 ]
机构：
[1] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA
[2] Cleveland Clin, Akron, OH USA
[3] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-211304
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5578 / 5579
页数：2
相关论文
共 50 条
  • [31] DOAC in the treatment of cancer-associated venous thromboembolism: a retrospective cohort study beyond the guidelines
    Cominacini, Mattia
    Suardi, Silvia
    Ferrari, Giulia
    Ciresa, Roberto
    Tosi, Federica
    De Marchi, Sergio
    Valenti, Maria Teresa
    Carbonare, Luca Dalle
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 5773 - 5779
  • [32] Incidence of Cancer-Associated Venous Thromboembolism (VTE): A Population-Based Cohort Study
    Ashrani, Aneel A.
    Heit, John A.
    Crusan, Daniel J.
    Petterson, Tanya M.
    Bailey, Kent R.
    Melton, L. Joseph, III
    BLOOD, 2008, 112 (11) : 1306 - 1306
  • [33] Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism
    Kimpton, Miriam
    Carrier, Marc
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (04) : 313 - 320
  • [34] Edoxaban for Cancer-Associated Venous Thromboembolism
    Frere, Corinne
    Dufilho, Monique
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01): : 94 - 94
  • [35] Rivaroxaban for cancer-associated venous thromboembolism
    Liang, Bo
    Liang, Yi
    Zhao, Li-Zhi
    Zhao, Yu-Xiu
    Gu, Ning
    SCIENCE PROGRESS, 2021, 104 (02)
  • [36] Incidence of cancer-associated venous thromboembolism
    Ballardini, P.
    Zangirolami, A.
    Margutti, G.
    Manfredini, R.
    ANNALS OF ONCOLOGY, 2006, 17 : XI70 - XI71
  • [37] Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer
    van der Hulle, Tom
    den Exter, Paul L.
    van den Hoven, Pim
    van der Hoeven, Jacobus J.
    van der Meer, Felix J. M.
    Eikenboom, Jeroen
    Huisman, Menno V.
    Klok, Frederikus A.
    CHEST, 2016, 149 (05) : 1245 - 1251
  • [38] The safety and efficacy of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study)
    Nakamura, M.
    Ishiguro, A.
    Dazai, M.
    Kawamoto, Y.
    Yuki, S.
    Sogabe, S.
    Hosokawa, A.
    Sawada, K.
    Muto, O.
    Umemoto, K.
    Izawa, N.
    Nakashima, K.
    Yagisawa, M.
    Kajiura, S.
    Mitsuhashi, Y.
    Ando, T.
    Sunakawa, Y.
    Kikuchi, Y.
    Yamanaka, T.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S577 - S577
  • [39] Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors
    Vlachostergios, Panagiotis J.
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (11): : 12386 - 12394
  • [40] Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting
    Durbin, Sienna M.
    Zubiri, Leyre
    Niemierko, Andrzej
    Bardia, Aditya
    Sullivan, Ryan J.
    McEwen, Corey
    Mulvey, Therese M.
    Allen, Ian M.
    Lawrence, Donald P.
    Cohen, Justine V.
    Hochberg, Ephraim P.
    Ryan, David P.
    Petrillo, Laura A.
    Reynolds, Kerry L.
    ONCOLOGIST, 2021, 26 (01): : 49 - 55
12345